Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepdegestrant and PF-07220060 in ER+/HER2- Advanced or Metastatic Breast Cancer
NCT06206837Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2024
- Primary completion
- Sep 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 8
01
Overview
A Phase 2 trial of vepdegestrant, atirmociclib in breast cancer, sponsored by Pfizer. Started Feb 2024; status: active, not recruiting.
02
Drugs
vepdegestrantatirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06206837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06206837.